Trials / Recruiting
RecruitingNCT06515730
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
RandomizEd compariSOn of Apixaban Versus Warfarin in Patients With Left VEntricular Thrombus After Acute Myocardial Infarction (RESOLVE-AMI)
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 212 (estimated)
- Sponsor
- Karolinska Institutet · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | 5 mg tablet twice a daily with dose reduction according to label |
| DRUG | Warfarin | 2.5 mg tablet once daily, with individual dosing according to coagulation tests |
Timeline
- Start date
- 2025-04-08
- Primary completion
- 2028-04-08
- Completion
- 2028-07-01
- First posted
- 2024-07-23
- Last updated
- 2025-07-01
Locations
16 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT06515730. Inclusion in this directory is not an endorsement.